News >

Role of PARP Inhibitors Developing in mCRPC

Danielle Bucco
Published: Tuesday, Dec 26, 2017

Prostate Cancer
PARP inhibitors are beginning to show promise for patients with metastatic castration-resistant prostate cancer (mCRPC).

In January 2016, the FDA granted olaparib (Lynparza) a breakthrough therapy designation as a treatment for patients with BRCA1/2 or ATM-mutated mCRPC who have received prior taxane-based chemotherapy and at least either enzalutamide (Xtandi) or abiraterone acetate (Zytiga). The decision is based on findings from the phase II TOPARP-A trial, which demonstrated that olaparib had a nearly 90% overall response rate in a subgroup of patients who had DNA-repair defects.

Additionally, there is an ongoing phase III trial (NCT02987543) investigating olaparib versus enzalutamide or abiraterone acetate in patients with mCRPC who have failed prior treatment with a new hormonal agent and have homologous recombination repair gene mutations.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Clinical Practice Connections™: New York Advanced Practice CollaborativeNov 15, 20191.25
Publication Bottom Border
Border Publication
x